Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Chronic, Acute and Neuropathic Pain Market Report 2016 - GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes - Research and Markets

Research and Markets
Posted on: 15 Sep 16

Research and Markets has announced the addition of the "Frontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes" drug pipelines to their offering.

The pain therapeutics market has been largely characterized by only incremental product innovation over the last decade, as most market segments continue to be dominated by long-established product categories, active pharmaceutical ingredients and concomitant mechanisms of action.

Moderate-to-severe pain has been and continues to be dominated by opioids, which are increasingly being reformulated to offer abuse-resistance, whereas mild pain is effectively treated with non-steroidal anti-inflammatory drugs (NSAID). However, significant unmet needs remain, as chronic pain subtypes - and particularly neuropathic pain - do not respond well to existing therapies, which do not align to the underlying molecular pathophysiological profile of pain.

However, strong unmet needs remain in core therapy types such as NSAIDs, which are associated with often severe gastrointestinal adverse events (AE), and opioids, which have a range of AEs associated with them - in addition to the potential for abuse, which has not been fully alleviated by the development of abuse-deterrent formulations.

The exceptionally large active pain pipeline, second only to breast cancer in terms of size, consists of 810 products across all stages of development, indicating that a great deal of resources are being invested into R&D, with the aim of ultimately overcoming the limitations of existing therapies.

Moreover, we identified 129 first-in-class programs in active development, constituting 20% of the pipeline for which there is a disclosed molecular target, and acting on 80 distinct first-in-class molecular targets. Although there is significant differentiation in the scientific rationale and clinical prospects across these first-in-class products, the majority of first-in-class targets demonstrate significant preclinical evidence, and alignment to molecular pathophysiological changes.

Key Topics Covered:

1 Tables & Figures

2 Executive Summary

2.1 Substantial Unmet Needs Remain in Core Therapy Types

2.2 Highly Diversified Range of Innovative Programs in Early Pipeline

2.3 Rich Pipeline Landscape with Numerous Investment Opportunities

3 The Case for Innovation

3.1 Growing Opportunities for Biologic Products

3.2 Diversification of Molecular Targets

3.3 Innovative First-in-Class Product Development Remains Attractive

3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation

3.5 Sustained Innovation

3.6 Research Report Guidance

4 Clinical and Commercial Landscape

5 Assessment of Pipeline Product Innovation in Chronic, Acute and Neuropathic Pain

5.1 Pain Pipeline by Molecule Type, Stage of Development and Molecular Target

5.2 Comparative Distribution of Programs between the Pain Market and Pipeline by Therapeutic Target Family

5.3 First-in-Class Pipeline Programs

5.4 First-in-Class and Established Pipeline Products by Pain Subtype

5.5 Table of All First-in-Class Pain Pipeline Products

6 Pain Pathophysiology and Innovation Alignment

6.1 The Complexity of Signaling Networks in the Central Nervous System

6.2 Matrix Assessment

7 First-in-Class Target and Pipeline Program Evaluation

7.1 Pipeline Programs Targeting Nerve Growth Factor and High Affinity Nerve Growth Factor Receptor

7.2 Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 16

7.3 Pipeline Programs Targeting Bradykinin B1 Receptor

7.4 Pipeline Programs Targeting Opioid Receptor-Like-1 Receptor

7.5 Pipeline Programs Targeting Purinoceptor 7

7.6 Pipeline Programs Targeting Metabotropic Glutamate Receptors 6 and 7

7.7 Pipeline Programs Targeting Calcitonin Gene-Related Peptide Type-1 Receptor

8 Deals and Strategic Consolidations

8.1 Industry-Wide First-in-Class Deals

8.2 Pain Deals Landscape

8.3 Licensing Deals

8.4 Co-development Deals

8.5 List of Pipeline Products without Prior Licensing or Co-Development Deal Involvement

9 Appendix

For more information about this drug pipelines report visit

Related Topics: Pharmaceuticals, Central Nervous System Drugs , Analgesics

View source version on

Business Wire

Last updated on: 15/09/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.